文献速递肝病消化道肿瘤与早癌

PGC1α通过PPARγ依赖性WNT/β-catenin/PDK1轴抑制Warburg效应从而抑制肝细胞癌转移

PPARγ Coactivator-1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ-Dependent WNT/β-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis.
PubMed 文献 · Hepatology · 2021-01-01

研究探讨PGC1α在肝细胞癌进展中的作用。人肝细胞癌中PGC1α表达下调,低表达与不良生存、血管侵犯和较大肿瘤尺寸相关。体外和体内实验显示PGC1α抑制肝癌细胞迁移和侵袭,机制上通过PPARγ激活抑制WNT/β-catenin通路,下调PDK1,从而抑制Warburg效应。

要点

  • 肝细胞癌中PGC1α表达下调,低表达提示预后不良。
  • PGC1α通过抑制Warburg效应抑制肝癌细胞迁移和侵袭。
  • 机制依赖PPARγ激活下调WNT/β-catenin通路进而抑制PDK1。

核心结论

  • 低水平PGC1α表达提示肝细胞癌患者预后不良。
  • PGC1α通过PPARγ依赖的WNT/β-catenin/PDK1轴抑制有氧糖酵解,从而抑制肝细胞癌转移。
  • PGC1α是预测肝细胞癌预后和治疗靶点的潜在因子。

研究设计与样本

  • 研究观察了人肝细胞癌中PGC1α的表达。
  • 临床研究分析了PGC1α表达水平与生存、血管侵犯和肿瘤大小的相关性。
  • 采用体外实验和体内小鼠模型研究PGC1α对肝癌细胞迁移和侵袭的影响及机制。

主要发现

  • 人肝细胞癌中PGC1α表达下调。
  • 低水平PGC1α表达与不良生存、血管侵犯和较大肿瘤尺寸相关。
  • 体外实验和体内小鼠模型显示PGC1α抑制肝癌细胞迁移和侵袭。
  • PGC1α通过下调PDK1抑制Warburg效应,该下调由WNT/β-catenin通路介导。
  • WNT/β-catenin通路的抑制由PPARγ激活诱导。

临床怎么用

  • PGC1α表达水平可能用于预测肝细胞癌患者预后。
  • PGC1α及其下游PPARγ/WNT/β-catenin/PDK1轴是肝细胞癌治疗的潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Peroxisome proliferator-activated receptor-gamma (PPARγ) coactivator-1α (PGC1α) is a key regulator of mitochondrial biogenesis and respiration. PGC1α is involved in the carcinogenesis, progression, and metabolic state of cancer. However, its role in the progression of hepatocellular carcinoma (HCC) remains unclear. APPROACH AND RESULTS: In this study, we observed that PGC1α was down-regulated in human HCC. A clinical study showed that low levels of PGC1α expression were correlated with poor survival, vascular invasion, and larger tumor size. PGC1α inhibited the migration and invasion of HCC cells with both in vitro experiments and in vivo mouse models. Mechanistically, PGC1α suppressed the Warburg effect through down-regulation of pyruvate dehydrogenase kinase isozyme 1 (PDK1) mediated by the WNT/β-catenin pathway, and inhibition of the WNT/β-catenin pathway was induced by activation of PPARγ. CONCLUSIONS: Low levels of PGC1α expression indicate a poor prognosis for HCC patients. PGC1α suppresses HCC metastasis by inhibiting aerobic glycolysis through regulating the WNT/β-catenin/PDK1 axis, which depends on PPARγ. PGC1α is a potential factor for predicting prognosis and a therapeutic target for HCC patients.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Zuo Q, He J, Zhang S, et al. PPARγ Coactivator-1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ-Dependent WNT/β-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis. Hepatology. 2021. PMID: 32298475. doi:10.1002/hep.31280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。